vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Rhea-AI Summary

vTv Therapeutics (VTVT) announced its participation in the virtual H.C. Wainwright 'HCW@Home' Series on June 12, 2025. The company, which focuses on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment, will participate in a fireside chat at 10:00 AM ET. Key company executives including Paul Sekhri (Chairman, President & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO), and Michael Tung (CFO) will engage in the discussion moderated by Emily Bodnar from H.C. Wainwright. The event will be accessible via webcast on the company's website.

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright “HCW@Home with vTv Therapeutics”
Format: Fireside Chat
Moderator: Emily Bodnar, Director, H.C. Wainwright
vTv Therapeutics Speakers:

• Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
• Thomas Strack, MD, Chief Medical Officer
• Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
• Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025
Time: 10:00 AM ET
Webcast Link: Register here

The webcast of the event will be accessible from News & Events page of the vTv website.

About vTv Therapeutics
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

What is the purpose of vTv Therapeutics' (VTVT) participation in the H.C. Wainwright conference?

vTv Therapeutics will participate in a fireside chat discussion to present information about their company and development of cadisegliatin, their potential first-in-class oral therapy for type 1 diabetes.

When and where will the VTVT H.C. Wainwright conference presentation take place?

The virtual presentation will take place on Thursday, June 12, 2025, at 10:00 AM ET through the H.C. Wainwright 'HCW@Home' Series.

Who are the key executives participating in VTVT's H.C. Wainwright presentation?

The presenting executives include Paul Sekhri (Chairman & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO), and Michael Tung (CFO), with Emily Bodnar from H.C. Wainwright moderating.

What is vTv Therapeutics' main drug candidate?

vTv Therapeutics' main drug candidate is cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for type 1 diabetes treatment.